Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

29.85
-1.0100-3.27%
Pre-market: 30.360.5100+1.71%08:22 EDT
Volume:236.78K
Turnover:7.08M
Market Cap:1.43B
PE:-9.78
High:30.62
Open:30.62
Low:29.45
Close:30.86
52wk High:52.93
52wk Low:23.75
Shares:47.98M
Float Shares:32.38M
Volume Ratio:0.87
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:3.39
PE(LYR):-10.42

Loading ...

Rapport Therapeutics CEO Abraham Ceesay Disposes of USD 143,276 in Common Shares

Reuters
·
16 hours ago

Rapport Therapeutics Initiated at Buy by Guggenheim

Dow Jones
·
Oct 06

Guggenheim Initiates Rapport Therapeutics at Buy With $65 Price Target

MT Newswires Live
·
Oct 06

Rapport Therapeutics initiated with a Buy at Guggenheim

TIPRANKS
·
Oct 06

Rapport Therapeutics COO Cheryl Gault Sells USD 332,992 of Common Stock

Reuters
·
Oct 02

Rapport Therapeutics CEO Abraham Ceesay Disposes of USD 87,135.01 in Common Shares

Reuters
·
Sep 25

Rapport drops after CEO presents at TD Cowen Neuropsychiatry Summit

TIPRANKS
·
Sep 24

Rapport Therapeutics Down over 16%, on Pace for Largest Percent Decrease in over a Year

Dow Jones
·
Sep 24

Analysts Offer Insights on NA Companies: Andersen Group, Inc. Class A (ANDG) and Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Sep 23

Rapport Therapeutics, Inc. (RAPP) Receives a Buy from TD Cowen

TIPRANKS
·
Sep 23

Rapport Therapeutics price target raised to $75 from $65 at BTIG

TIPRANKS
·
Sep 16

Rapport Therapeutics, Inc. : Btig Raises Target Price to $75 from $65

THOMSON REUTERS
·
Sep 16

U.S. Research Roundup-Domino's, McDonald's, Starbucks

Reuters
·
Sep 16

Rapport Therapeutics CEO Abraham Ceesay Sells $373,980 of Common Shares

Reuters
·
Sep 10

Analysts Conflicted on These NA Names: Fiserv (FISV) and Rapport Therapeutics, Inc. (RAPP)

TIPRANKS
·
Sep 02

Rapport Therapeutics to Join Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 02

Rapport Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram Disposes of Common Shares Worth $2.51 Million

Reuters
·
Aug 27

Rapport Therapeutics to Host Virtual KOL Event on Bipolar Mania and RAP-219 Program

Reuters
·
Aug 24

Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram Disposes of 404 Common Shares Worth $20,159.6

Reuters
·
Aug 21